Skin Tech Pharma Group's RRS® HA Long Lasting Triumphs at AMWC 2026

In a significant achievement for the aesthetics sector, Skin Tech Pharma Group proudly announces that its flagship injectable, RRS® HA LONG LASTING, has received the prestigious award for Best Injectable in the Skin Revitalization category during the AMWC 2026 event. This accolade highlights the company's leadership position in the emerging Skin Builder market and reinforces its commitment to innovation and quality in aesthetic medicine.

A Milestone Achievement

Since its launch in 2021, RRS® HA LONG LASTING has rapidly established itself as a groundbreaking product, boasting over one million treatments administered globally. It has garnered recognition not only for its safety and clinical effectiveness but also for its ability to redefine aesthetic treatments by improving skin quality and restoring a natural appearance.

The award reflects a growing demand for treatments that provide natural-looking results while promoting long-term skin health, tissue quality, and graceful aging. According to Márcio Rodrigues, CEO of Skin Tech Pharma Group, “Receiving this award is a significant milestone for us and is a testament to the strength of our long-term strategy. As the landscape of aesthetic medicine continues to evolve, our ambition is to lead through scientific rigor, differentiated innovation, and a deep understanding of healthcare professionals' needs.”

Understanding RRS® HA Long Lasting

RRS® HA LONG LASTING stands out in the market as the ultimate skin builder, integrating the best features of skin stimulators and dermal fillers. This unique injectable combines cross-linked hyaluronic acid with a protective buffer of 15 amino acids, which work synergistically to support the dermal structure. The result is improved hydration, firmness, and texture, along with a subtle lifting effect that alleviates fine lines and wrinkles.

Patients can expect immediate and natural results with progressive enhancements in skin quality, supported by a high and proven safety profile. This is the first skin stimulator developed with a dual-action approach, addressing skin aging holistically by targeting both skin quality and the restoration of natural facial volume within a single treatment session.

Thanks to its advanced technology, RRS® HA LONG LASTING promotes gradual improvements in skin quality, allowing patients to leave the clinic with a visible immediate effect, coupled with an ongoing enhancement in skin appearance over the following weeks. This dual approach not only facilitates natural results but also leads to high patient satisfaction.

Expert Endorsements

Clinical applications have consistently shown improvements in skin texture, elasticity, and overall radiance. Dr. Javed Hussain, a key opinion leader for Skin Tech Pharma Group, notes, “This ultimate skin builder is defined by its hyaluronic acid structure combined with a protective amino acid buffer solution. It provides essential components for restoring natural dermal function, which declines with age. In practice, results are reproducible, reliable, and meet safety expectations, offering a level of durability not typically associated with traditional skin stimulators.”

About Skin Tech Pharma Group

For 30 years, Skin Tech Pharma Group S.L.U. has been a global leader in aesthetic medicine, producing high-quality medical devices and advanced cosmeceutical products. Founded in 1994 by Dr. Philippe Deprez and based in Costa Brava, Spain, it is backed by Charterhouse Capital Partners and EXCELSIS. The launch of Easy TCA® in 1996 established the company as a pioneer in the industry. With a state-of-the-art internal laboratory and a global research and development team, Skin Tech combines aesthetic performance with pharmaceutical rigor, offering reliable, evidence-based solutions worldwide.

To learn more about RRS® HA LONG LASTING and its revolutionary capabilities, visit Skin Tech Pharma Group.